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From fundamental supramolecular chemistry to
self-assembled nanomaterials and medicines and
back again – how Sam inspired SAMul
David K. Smith
This feature article provides a personal insight into the research from my group over the past 10 years.
In particular, the article explains how, inspired in 2005 by meeting my now-husband, Sam, who had
cystic fibrosis, and who in 2011 went on to have a double lung transplant, I took an active decision to
follow a more applied approach to some of our research, attempting to use fundamental supra-
molecular chemistry to address problems of medical interest. In particular, our strategy uses self-assembly
to fabricate biologically-active nanosystems from simple low-molecular-weight building blocks. These
systems can bind biological polyanions in highly competitive conditions, allowing us to approach
applications in gene delivery and coagulation control. In the process, however, we have also developed
new fundamental principles such as self-assembled multivalency (SAMul), temporary ‘on–off’ multiva-
lency, and adaptive/shape-persistent multivalent binding. By targeting materials with applications in drug
formulation and tissue engineering, we have discovered novel self-assembling low-molecular-weight
hydrogelators based on the industrially-relevant dibenzylidenesorbitol framework and developed
innovative approaches to spatially-resolved gels and functional multicomponent hybrid hydrogels. In this
way, taking an application-led approach to research has also delivered significant academic value and
conceptual advances. Furthermore, beginning to translate fundamental supramolecular chemistry into
real-world applications, starts to demonstrate the power of this approach, and its potential to transform
the world around us for the better.
Beginnings
In 2006, I published a feature article in Chemical Communications.1
By that point, I had been an independent academic in York for
7 years and had developed a research programme exploring
fundamental supramolecular chemistry. This built on my
scientific training with Prof. Paul Beer at University of Oxford
and Prof. Francois Diederich at ETH Zurich, which gave me a
love of understanding how molecules interact with one another.
Interactions between molecules can be considered analogous
with interactions between people that have always fascinated
me. I love to teach and do outreach, probably inspired by a long
line of teachers in my family, all the way back to my Great
Grandmother. Furthermore, my own education at a compre-
hensive school in Stockport demonstrated the value of those
teachers that were able to eﬀectively marshal their inter-
personal interactions – exactly like the molecules we now try
to manipulate. Just before writing that feature article 12 years
ago, I made my own most important inter-personal interaction,
with my husband-to-be, Sam. In many cases, as a research
chemist, this would not matter, but in my case, this single event
led to a radical change in how I approached research. This article
aims to tell that story.
Sam has cystic fibrosis – the genetic disease that encodes
faults in chloride transport proteins within the cell membrane,
which in turn causes mucus build-up around cells.2 This problem
Department of Chemistry, University of York, Heslington, York, YO10 5DD, UK.
E-mail: david.smith@york.ac.uk
Dave Smith is Professor of Chemistry at University of York, UK,
publishing 4150 research papers and with an h-index well over
50. He is a passionate educator with a strong belief in widening
participation, giving outreach lectures to 450 000 UK school
students and developing his own YouTube chemistry channel,
with 4500 000 views. Dave has received the RSC Corday Morgan
Award and a National Teaching Fellowship from the Higher
Education Academy. He was one of C&ENs Top 20 Chemists to
Follow on Twitter (@professor_dave), one of the RSC’s 175 diverse
‘Faces of Chemistry’ and was shortlisted for a ‘Gay Times’ Honour.
Dave entered into a civil partnership with his husband Sam in
2010. They live in central York, with their adopted son – they enjoy
the vibrant, historic city, and like cooking & travelling.
Received 3rd March 2018,
Accepted 3rd April 2018
DOI: 10.1039/c8cc01753k
rsc.li/chemcomm
ChemComm
FEATURE ARTICLE
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
6 
A
pr
il 
20
18
. D
ow
nl
oa
de
d 
on
 2
7/
04
/2
01
8 
09
:0
6:
28
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal
Chem. Commun. This journal is©The Royal Society of Chemistry 2018
is particularly acute in the lungs, where the mucus hosts
bacterial infections that ultimately lead to severe lung damage
and early death. When I met Sam, my research team was
pioneering an understanding of self-assembled gels in organic
solvents3 and anion recognition events in non-aqueous media.4
I was, and indeed still am, very proud of this research, but
explaining to someone with a life-limiting condition that you
are using all of your skills to understand how peptides interact
with one another in toluene somehow felt inadequate. I therefore
became determined that some of our research would approach
problems that might make a difference, specifically in CF-related
medicine. In terms of supramolecular chemistry, this defines a
clear challenge: for research to be medicinally or biologically
relevant, you have to work in highly competitive media – for
example water, and more likely serum, plasma, or even blood.
This makes supramolecular nanomedicine highly challenging.5
We therefore speculated that by targeting medicinal applications,
important new fundamental insights and guiding principles may
also emerge.
From DNA binding to gene delivery
Perhaps the most widely discussed potential CF treatment is
gene therapy – delivering a ‘healthy’ copy of the faulty gene to
cells, where it can subsequently generate the required protein.6
Such an approach could treat cystic fibrosis at source, rather
than just alleviating symptoms, as most current therapies aim
to do. DNA is a polyanion, and I had expertise in binding
anions dating back to my own PhD,7 so this therefore seemed
to be a way of applying my knowledge to a problem of interest.
Considering my own background in dendrimer chemistry,8 and
the well-known capacity of dendritic molecules to achieve gene
delivery,9 I had previously considered this area of research, but
had rejected it as being too competitive. Now I had a real reason
to join the competition.
We decided to develop an innovative biomimetic approach
to DNA binding and delivery. Given the well-known ability of
multivalent displays of ligands to enhance binding aﬃnities,10
we designedmultivalent arrays of bio-inspired DNA-binding ligands.
An eﬀective naturally-occurring DNA binder is spermine,11 present
in sperm. This compound was first isolated in crystalline form from
human semen by van Leeuwenhoek in the late 17th century,12
testimony to its very high concentrations in seminal fluid. Spermine
is also present at micromolar levels in all eukaryotic cells. It has
pKa values that are optimised for DNA binding, is present as a
tetra-cation at physiological pH, and is an appropriate shape to
bind within the minor groove of DNA. However, the binding of
an individual spermine unit to DNA has relatively low aﬃnity.13
For this reason, relatively large concentrations are required
in vivo to achieve control over DNA.
We reasoned that displaying spermine ligands in a multi-
valent manner may enhance the binding aﬃnity, and our initial
design therefore simply displayed these ligands on the periphery
of dendritic architectures (G1-SPM and G2-SPM, Fig. 1A).14 Nona-
valent G2-SPM was a highly eﬀective DNA binder, with binding
aﬃnities eﬀectively independent of salt concentration (i.e.,
ionic strength). Conversely, the binding of trivalent G1-SPM to
DNA was weaker, and was adversely aﬀected by physiological
salt concentrations. This intriguing phenomenon was challen-
ging to fully rationalise. At around this time, I joined a highly
productive COST network (TD0802) focussing on Dendrimers in
Biomedicine.15 Indeed, EU networking has been a huge part of
the last 12 years of research. As a part of this network, I met the
irrepressibly energetic Prof. Sabrina Pricl from University of
Trieste, who persuaded me multiscale modelling was a vital
complement to our experimental work. This in silico approach
can help understand binding mechanisms and design agents
ab initio with greater activity. Sabrina has become a close colla-
borator and a great personal friend. In 2009, in a key paper, we
proposed the underlying mechanism by which G2-SPM resists
competitive salt ions at the binding interface – a ‘screening
and sacrifice’ model.16 Not all of the nine spermine ligands
actively bind to DNA and in high salt conditions, more of the
ligands sacrificed their interactions, but then acted to screen
the remaining binding sites, which achieved significantly
enhanced affinity (Fig. 1B). We therefore demonstrated an
important new advantage of having flexible multivalent arrays
under these highly competitive binding conditions (Fig. 1C).
Pleasingly, this demonstrated that wholly new fundamental
insights can arise from work that starts out with a specific
application in mind.
Fig. 1 (A) Dendrons G1-SPM and G2-SPM designed as multivalent DNA
binders. (B) Graph derived from molecular dynamics indicating that on
addition of high concentrations of salt the overall binding is hardly aﬀected –
a result of several ligands (SPM6 and SPM8) sacrificing all interaction with
DNA while other ligands (SPM2 and SPM5) then optimise their binding via
shielding. (C) Image from molecular dynamics (MD) simulation of G2-SPM
(skeletal structure) bound to DNA (blue and red ribbons) in the presence of
NaCl (purple/green).
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Given the strength of interactions between G2-SPM and
DNA, we recognised that degradation of our DNA binders would
be important if we were to achieve eﬀective gene delivery. Our
synthetic approach was therefore modified to change Newkome-
type amide–ether dendritic scaffolds,17 into Fre´chet–Hult type
ester-derived dendrons (G1-Ester, G2-Ester and G3-Ester, Fig. 2,
top).18 Fre´chet–Hult dendrons had been reported to degrade
under biologically-relevant conditions.19 Displaying our DNA
binding ligands on the surface of such systems yielded dendrons
that exhibited ‘on–off’ multivalency.20 This was a new concept,
developed by us, in which the synthetic construct initially has
ultra-high-affinity for its target owing to its multivalent structure,
but after degradation, the multivalent array is destroyed, and all
ability of the compound to intervene in biological pathways is
lost. We reasoned this approach would assist with intracellular
DNA release and limit the persistence and potential toxicity of
our nanoscale delivery vehicles – a problem often associated with
dendrimers and other nanosystems in vivo.21 We also developed
dendrons in which a photo-cleavable linker was inserted
between the dendron and the ligand display, so that UV irradia-
tion led to triggered loss of the ligands from the surface of the
dendron (Fig. 2, bottom) hence switching off the ultra-high
affinity DNA binding event.22
In addition to tuning the framework of the dendron to
introduce degradability, we also tuned the ligands on the
surface (e.g. G1-SPM, G1-DAPMA, G1-DAP, Fig. 3).23 We found
that naturally occurring SPM ligands were the most eﬀective for
DNA binding, but that less eﬀective DAPMA ligands actually gave
somewhat better gene delivery profiles. Molecular dynamics was
insightful in understanding the thermodynamic impact of
ligand modification. Although the enthalpic contribution to
binding was roughly proportional to the dendron surface
charge, dendrons with DAPMA surface amines had significant
entropic costs of binding to DNA. This is a consequence of the
fact that for this diamine more of the dendron structure has to
be organised in order for multiple charges to make eﬀective
contact with DNA, while for SPM, each surface ligand is already
an optimised triamine, giving each individual charge a lower
entropic cost of binding. Furthermore, the hindered tertiary
amine in DAPMA bound particularly strongly to the DNA double
helix leading to ligand back-folding and geometric distortion of
the DNA. Although this weakens binding, we suggested it might
explain enhanced gene delivery, as DNA compaction and release
are both important steps.
From multivalency to self-assembled
multivalency (SAMul)
All of the systems described above, however, had significant
synthetic complexity, and relied on relatively elaborate covalent
synthesis to create multivalent ligand displays. We therefore
wondered if instead of using covalent synthesis to form higher
generation multivalent dendrons, we could use a self-assembly
step to multiply up smaller low-aﬃnity binding arrays into larger
high-aﬃnity nanostructures. This approach is intermediate between
the two main approaches to non-viral gene delivery vectors,
which rely on either cationic polymers24 or cationic lipids.25
Fig. 2 (top) Structure of degradable DNA binding dendrons capable of
‘on–off’ multivalency based on the Fre´chet–Hult scaffold, and (bottom)
schematic of UV-degradable dendrons including a photo-cleavable linker
between the dendron and the SPM ligands, indicating cleavage of dendron
and loss of DNA binding ability.
Fig. 3 (top) Structures of dendrons with diﬀerent ligands and (bottom)
snapshots of molecular dynamics simulation of dendrons binding to
double helical DNA: (A) G2-DAP, (B) G2-DAPMA and (C) G2-SPM. Within
the dendron CEN is shown in blue, REP in yellow and the amine ligands are
shown inmagenta (DAP), green (DAPMA) and red (SPM). The DNA is portrayed
as a dark gray shadow, water molecules are omitted for clarity, and only those
counterions in close proximity to the complexes are shown.
ChemComm Feature Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
6 
A
pr
il 
20
18
. D
ow
nl
oa
de
d 
on
 2
7/
04
/2
01
8 
09
:0
6:
28
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Chem. Commun. This journal is©The Royal Society of Chemistry 2018
We reasoned that our systems may combine some of the
advantages of each of these diﬀerent classes of vector.
Initially, we simply modified the focal point of our existing
dendrons with hydrophobic units (e.g. Chol-G1, Chol2-G1, and
Chol-G2, Fig. 4).26 Pleasingly, converting a simple benzyloxy-
carbonyl protecting group at the focal point of our small first
generation dendrons into a cholesterol unit, to make Chol-G1
switched on ultra-high aﬃnity binding of DNA. Furthermore,
although Chol-G2 had a much larger binding array than Chol-G1
it was actually much less eﬀective (i.e. less is more).27 Multiscale
modelling studies indicated that Chol-G2 is unable to self-
assemble eﬀectively as it is dominated by the hydrophilic, large
dendritic head group – the poorly packed SAMul nanostructure
therefore had a much lower surface charge density (Fig. 4B). This
demonstrates the importance of balancing the potential of self-
assembly andmultivalency to optimise binding. We were not the
first in the literature to recognise that self-assembly could
organise multivalent ligand displays – indeed, this was reported
by the Whitesides group as early as 1992,28 but we did bring this
disparate field together in a key review of the quantitative studies
of self-assembled multivalency.29 We went on to refer to self-
assembled multivalency as ‘SAMul’, in honour of my husband,
Sam (Samuel) Smith.
It is tempting to think that a SAMul binding eﬀect will either
be turned ‘on’ or ‘oﬀ’ depending simply on whether or not the
system is, or is not, self-assembled. However, in a structure–
activity relationship study we varied the hydrophobe and found
that this simple relationship was not the case.30 Hydrophobes
that were better able to drive self-assembly gave rise to self-
assembled micellar nanostructures with higher surface charge
densities. Indeed the cationic charge density could be tuned
across a range. These systems then showed tunable DNA binding
affinities primarily as a result of their different charge densities,
resulting from the hydrophobic tuning. This clearly demon-
strates that SAMul systems can have tunable binding affinities
depending on the precise structure.
When modified with hydrophobic units, the gene delivery
potential was also enhanced26 over the baseline results for the
non-self-assembling dendrons.31 We reasoned that the cationic
lipid nature of these systems assists delivery – it is known that
lipids can enable endosomal escape, via a flip-flop mechanism.32
The best vector was Chol2-G1, which has a relatively large
hydrophobic component. Multiscale modelling suggested this
system could assemble into cylindrical micelles at elevated con-
centrations typical of, for example, endosomes, and form a
hexagonal phase.27 This is in accord with Israelachvili principles of
self-assembly that state that the hydrophobic/hydrophilic ratio of
lipids program-in the preferred assembly mode of surfactants.33
It is known that lipids capable of forming hexagonal phases are
preferred for endosomal escape.34 We also found there were
synergistic advantages for gene delivery of mixing lipid-like and
polymer-like systems.
We explored relatedmorphological eﬀects on the self-assembly
of multivalent systems using a series of RGD-peptide modified
lipids. RGD peptides can enhance cell targeting owing to inter-
actions with integrin receptors on cell surfaces35 – we developed
such systems to mix into our gene delivery vehicles and enhance
delivery. We initially demonstrated that self-assembled RGD-
peptides bound integrins as effectively as covalent dendritic
multivalent equivalents – a clear SAMul effect.36 Once again, the
hydrophobic/hydrophilic balance modified the morphology of
the SAMul systems.37 Spherical assemblies performed better in
our integrin binding assay than cylindrical micelles, possibly
because of the more effective ligand display, with each head
group having more space at the highly curved spherical surface,
therefore demonstrating that SAMul binding responds to nano-
scale morphology.
In a key study, we brought together our new concepts, and
reported a family of degradable SAMul dendrons (e.g. Chol-
G2Ester-DAPMA, Chol2-G2Ester-DAPMA and C22-G2Ester-DAPMA,
Fig. 5) and explored their DNA binding and gene delivery
potential.38 Although these compounds showed useful degradation
profiles under physiological conditions of pH and ionic strength,
they did not degrade once bound to DNA. We determined that
hydrolysis of the esters within the structure was accelerated by the
peripheral amine ligands via an intramolecular catalytic accelera-
tion at physiological pH (Fig. 5B). Hydrolysis was switched oﬀ at
lower pH values (owing to amine protonation) and in the presence
of DNA (owing to amine–DNA binding). Sadly, this degradation
profile was therefore less useful for gene delivery in vitro and DNA
release is problematic. As such, these results were somewhat
disappointing – although they led to significant breakthroughs
in other potential areas of therapy, as described later.
Fig. 4 (A) Systems developed for the self-assembled multivalent (SAMul)
approach to DNA binding. (B) Mesoscale modelling demonstrating that
Chol-G1 actually has a higher cationic surface charge thanChol-G2 as a result
of its more eﬀective assembly – ‘less is more’. (C) Mesoscale modelling at
elevated concentrations of self assembled Chol-G1 (a), Chol-G2 (b) and
Chol2-G1 (c) shown in green binding to DNA shown in red. Note the different
cylindrical morphology preferred by Chol2-G1.
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In addition, we co-assembled PEG lipids with a SAMul
dendron to modify the DNA binding aﬃnity.39 One of these
modified the ability of the co-assembly to cross a model mucus
layer, an important step in therapeutic delivery to the CF lung.
We rationalised these eﬀects in terms of a balance between the
mucoadhesivity due to the surface charge of the nanoscale
aggregates and that due to the PEG groups. This clearly demon-
strated the potential of co-assembly as a simple strategy for
modifying and optimising the performance of SAMul systems for
biomedical use.
We also reported a ‘double degradable’ approach to SAMul
systems in which a disulfide linker was incorporated between the
hydrophobic unit and the multivalent head group (Chol-SS-G2-
Ester, Fig. 6).40 This allows these structures to undergo triggered
reductive cleavage, with dithiothreitol (DTT) inducing controlled
breakdown, enabling the release of bound DNA – another
example of temporary ‘on–off’ multivalency. Furthermore,
because the multivalent dendrons are constructed from esters,
a second slow degradation step takes place converting the
dendron into very small molecular-scale building blocks, clearly
illustrating the potential of such self-assembled systems including
multiple degradable units.
To further translate our approach towards the clinic, in
collaboration with Rainer Haag, Marcelo Calderon and co-workers
in Berlin, we developed SAMul systems using the general principles
described above but with modified molecular designs. For example,
our SAMul concept was combined with UV-degradable linkers
to generated SAMul systems that were switched oﬀ by UV
irradiation.41 We also developed other systems (e.g., G2-Ether
(A1), Fig. 7) and tested them for siRNA delivery both in vitro and
in vivo.42 The ester was in a diﬀerent orientation to our previous
design, and further from the focal point of the dendron, which
was active for siRNA delivery, eﬀectively achieving gene silencing
in the tumour cell line 786-O (Fig. 7B). It was reasoned that the
ester had an eﬀective degradation and siRNA release pathway.
Pleasingly, in vivo studies demonstrated that these delivery
vehicles, when combined with siRNA, did not elicit major
Fig. 5 (A) Structures of SAMul degradable dendrons. (B) Degradation of
dendron at pH 7.5 with stability at pH 5.0. (C) Computational modelling of
degradation and disassembly of SAMul dendron array demonstrating how
in principle, DNA release should be achieved.
Fig. 6 Double degradable SAMul DNA binding arrays which disassemble
as a result of disulfide reduction and ester hydrolysis and the structure of
Chol-SS-G2-Ester which possesses two diﬀerent types of degradable unit.
Fig. 7 (A) Structure of dendron developed in collaboration with Haag and
co-workers. (B) 786-O Luc transgenic cells were transfected with luciferase
specific and non-targeting siRNA at N/P ratios of 10, 20, and 30 for 48 h.
Lipofectamine was used as a positive control and untreated cells as the
negative control. (C) In vivo study of mice treated intravenously with
8 mg kg1 and 20 mg kg1 complexed with non-targeting siRNA at N/P ratios
of 25, or Invivofectamine. Retrobulbar blood was taken 1 h after injection and
serum was examined via Meso Scale Discovery Multi-Spot Assay System,
Mouse ProInflammatory 7-Plex Assay Ultra-Sensitive Kit. Results are shown as
mean  SD of triplicates.
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pro-inflammatory cytokine response when tested in vivo in mice
(Fig. 7C). Such responses are a frequent problem with gene
delivery vehicles,43 and other nanoscale therapeutics, and their
absence is very desirable. We anticipate such systems will go on
to further development.
We are also delighted that other researchers have applied
our SAMul methodology with a high degree of success to siRNA
delivery. Notably Ling Peng and her research team developed
self-assembling dendritic systems that showed high levels of
activity in vitro and considerable potential in vivo.44 We are also
now working with researchers across the EU to try and translate
some of our gene delivery vectors further, with the ultimate goal
of making an impact on cystic fibrosis healthcare. We hope
that, in one way or another, enhanced treatments may be
forthcoming from key concepts developed here in York, such
as SAMul binding and temporary (‘on–off’) multivalency.
How major surgery inspired SAMul
heparin binders and sensors
In 2010, around the time of our civil partnership, Sam’s health
rapidly deteriorated, and his lung function dropped to just
20%. For cystic fibrosis patients with heavily progressed disease
like this, the only clinical option is lung transplantation. Sam
was listed for transplantation and was fortunate enough to
receive a transplant at the Freeman Hospital (Newcastle) in
January 2011. Obviously, this was a hugely stressful period in
both of our lives. However, once again, it gave me plenty of
opportunity to reflect on the chemistry we were doing and other
uses it may find. On discussion with surgeons and anaesthetists,
I realised that a key drug during surgery was heparin – a
polyanionic saccharide that acts on the thrombin cascade pre-
venting undesired coagulation and clotting.45 Once surgery is
complete, and the patient is returned to the ward, it is important
to achieve homeostasis so that clotting and recovery can begin.
This is achieved using a heparin-binding agent, protamine,
which removes heparin from the bloodstream, enabling clotting.
Protamine is a polycationic protein, which binds heparin via
electrostatic ion–ion interactions using its multiple arginine
residues.46 However, a significant number of patients have
adverse responses to protamine,47 meaning it cannot be used
in high doses, giving rise to problems with ‘heparin rebound’,48
when heparin desorbs from plasma proteins some hours later
leading to bleeding. I therefore learned there was significant
interest both in binding heparin (to remove it once surgery is
complete) and sensing heparin (to determine precisely how
much is present in vivo). There have been a number of synthetic
approaches to both heparin binding49 and heparin sensing,50
and we have reviewed this area of translational supramolecular
chemistry.51
While I was sat at Sam’s bedside, I reflected on the fact that
some of our gene delivery agents, which bind polyanions as
described above, suﬀered from the problem of degrading in
the absence of DNA, but not when bound to it.38 Although
problematic for gene transfection, this is potentially useful for
heparin binding – indeed, the ideal heparin rescue agent should
be stable when bound to heparin, so excretion of the intact
complex can occur, but should degrade if present in excess. This
would potentially allow the patient to be dosed with relatively
large amounts of the active agent, as unbound material would
degrade into non-toxic by-products. In the case of self-assembled
multivalent (SAMul) systems, degradation will also switch off
high-affinity binding and thus prevent intervention in other
biological pathways.
We therefore developed a simple SAMul system C22-G1
(Fig. 8) that could bind heparin with high aﬃnity.52 This system
self-assembled into nanostructures at low concentration (4 mM),
displaying cationic ligands capable of heparin binding. The
linker between ligands and hydrophobe contained an ester,
capable of degrading under physiological conditions. When
dried, C22-G1 nanostructures were surprisingly robust, and even
in the presence of strongly binding heparin, transmission
electron microscopy (TEM) indicated they did not change their
spherical nanoscale morphologies, suggesting good stability. On
drying with heparin, the micelles organised around the poly-
anionic heparin to form hierarchical aggregates. More recent
studies in collaboration with Mauri Kostiainen have fully char-
acterised the organisation of cationic spherical micelles with
polyanionic heparin using small angle X-ray scattering and
multiscale modelling.53 This is hierarchical electrostatic self-
assembly, in which spherical cationic assemblies close-pack with
cylindrical anionic polymers to give face-centred-cubic arrays
ca. 50–250 nm in size.
In a later study, we fully characterised C22-G1 nanostructures
in solution using dynamic light scattering (DLS). and quantified
the binding ability of C22-G1 in more detail. In buﬀer, C22-G1
was a more eﬀective heparin binder than protamine (Fig. 8).54
Furthermore, comparison of the heparin binding of C22-G1 with
an analogue with no hydrophobic unit demonstrated that the
Fig. 8 Structure of C22-G1, multiscale modelling simulation of C22-G1
self-assembled into a multivalent structure and bound to heparin, and
binding study comparing the ability of C22-G1, current therapy protamine,
and a non-self-assembling precursor (P-G1) indicating that in buﬀer, the
self-assembling nanosystem outperforms protamine, and that there is a
clear quantifiable SAMul binding eﬀect.
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C22 chain switches on high-aﬃnity binding – a clear SAMul
effect. However, the presence of serum somewhat disrupted the
ability of C22-G1 to self-assemble and hence bind heparin – we
reasoned this was due to the C22 unit interacting with serum
albumin proteins. This can be a problem with self-assembled
systems, which can be kinetically labile, and hence disassemble
in the presence of competitive influences.55 Nonetheless, this
lead compound was active in the PT anti-coagulation assay in
human plasma, reversing the anti-coagulant effect of heparin
when applied at a clinically useful dose – demonstrating that the
SAMul approach can operate in highly competitive, biologically
relevant media. We have further stabilised our heparin binders
in competitive conditions and developed unpublished modified
lead compounds for potential in vivo study.
We have reported the impact of self-assembled morphology
on heparin binding using (C12)2-Lys and (C12)2-Lys-Lys2 (Fig. 9).
56
As a result of their hydrophobic/hydrophilic ratios, the former
compound assembles into worm-like micelles while the latter
forms spherical micelles. Although the spherical micelles bind
heparin more eﬀectively in buﬀer because of their more open
surfaces and better ligand display, the cylindrical micelles have
greater stability against competitive influences, and better
maintain their binding ability when buﬀer is replaced with
human serum.
We have also developed heparin sensors. In part, we wanted
a heparin sensor for rapid quantification of the relative abilities
of our heparin binders via a dye displacement assay. However,
there is also a clinical need for heparin sensors that could
rapidly assess the total heparin load in a patient’s bloodstream,
allowing anaesthetists to accurately provide a patient with addi-
tional heparin, or heparin-rescue agent. At present, heparin
sensing is achieved by performing coagulation assays on blood
samples – a relatively time-consuming, off-line process – clearly
there is scope to improve this. Amongst heparin sensors in
the literature, Azure A was reported to work in highly competitive
conditions, and should have been ideal for our purposes.57
However, we were unable to reproduce this, and noted the
original experiments were not buffered and may have suffered
from pH changes. We therefore decided to develop a new dye
with higher affinity towards heparin by modifying the well-
known dye thionine acetate with cationic arginine units.58 This
was achieved using a simple two-step methodology based on
peptide coupling and deprotection in a pleasing overall yield
(Fig. 10). We named the resulting dye ‘Mallard Blue’ (MalB)
after the steam train of the same colour, which holds the world
speed record and is housed in the National Railway Museum
here in York (ever since I was a boy I have always loved trains!).
This dye is an effective heparin sensor in highly competitive
media, and can rapidly detect heparin at clinically relevant con-
centrations in human serum.
Using MalB, we developed a dye displacement assay for
quantification of the performance of heparin binders.59 To
demonstrate this assay in action, a family of dendritic com-
pounds with the capacity to bind heparin was investigated –
flexible PAMAM dendrimers and more rigid ‘Transgeden’ (TGD)
dendrimers (which have peripheral PAMAM units attached to a
conjugated core).60 This study indicated fundamental differences
between these two families of dendrimers. In the presence of
excess heparin, a clinically relevant situation at the start of
heparin rescue, TGD outperforms PAMAM because the rigidity
of TGD means small clusters/patches of surface amines are
locally well-organised for binding. However, when less heparin
is present (towards the end of heparin rescue), the overall rigid
nanoscale structure of TGD is not sufficiently flexible to maxi-
mise all of its contacts with a single heparin binding partner
(Fig. 11). We described TGD as showing shape-persistent multi-
valency. Conversely, in PAMAM dendrimers, the individual
surface ligands are not so well locally optimised for target
binding, but the flexibility of the overall nanostructure allows it
to adapt its global shape more easily and hence maximise the total
number and efficiency of contacts with the binding partner
(Fig. 11). We referred to this behaviour as adaptive multivalency.
We suggest that these fundamental differences are of considerable
Fig. 9 Compounds (C12)2-Lys and (C12)2-Lys-Lys2 have diﬀerent hydrophobic/
hydrophilic ratios and diﬀerent molecular shapes, which give rise to self-
assembled nanostructures with diﬀerent morphologies – cylindrical micelles
and spherical micelles respectively – as indicated by multiscale modelling.
Fig. 10 Synthesis of Mallard Blue based on modification of thionine
acetate with Boc-protected arginine, followed by Boc deprotection. (inset)
UV-vis response of MalB to the addition of heparin.
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significance in multivalent binding. Once again therefore,
adventures into applied research gave rise to new insights.
To develop heparin sensor technology further, it was desir-
able to develop sensors with an easily detectable fluorescent
output, at two diﬀerent wavelengths for ratiometric sensing. We
therefore developed a heparin sensor incorporating pyrene.61
In buﬀered water, the sensor formed self-assembled multi-
valent (SAMul) nanostructures providing it with a significant
(order of magnitude) improvement in dynamic range. Further,
it gave a naked eye response unlike other pyrene derivatives. At
elevated heparin concentrations, SAMul-enhanced sensing was
also observed even in 100% serum. However, SAMul-enhanced
sensing did not persist in serum at biomedically relevant con-
centrations. It is therefore interesting to reflect just how good
the heparin sensing capacity of Mallard Blue is, being able to
detect the polyanion at very low concentrations even in highly
competitive conditions. This dye must be particularly opti-
mised for the structural motifs dominant in heparin. Indeed,
these observations led us to reflect on the role structural
optimisation plays in electrostatic binding.
Selectivity in electrostatic binding –
towards the polyanion world
Once involved in electrostatic polyanion binding, perhaps the
most commonly asked question, is the extent to which selec-
tivity can be designed into such systems. Many a paper reviewer
or conference attendee has noted that ‘any polycation can bind
any polyanion’ – one adding that ‘even Monsieur Coulomb
himself would not have been surprised by these results’.
Obviously, there is some truth in this, and models of ion–ion
binding suggest that charge density plays a controlling role with
deviations from this being rare.62 Indeed, even biology can struggle
to achieve selectivity between different polyanionic targets – for
example, it is known that DNA and heparin can, in some cases,
both bind to the same protein targets.63 However, biology is a
polyanionic world – nucleic acids, cell membranes, glycosamino-
glycans, proteoglycans, tubulins, etc. are all negatively-charged.64
Increasingly, there are hints that some selectivity can be achieved
in the polyanion world – for example, consensus sequences have
been discovered for heparin binding, which would suggest that
certain motifs evolved for this purpose.65 Nonetheless, achieving
any degree of selective recognition using synthetic systems would
appear to be a challenging fundamental target and it captured
our attention.
We developed chiral SAMul systems that achieved enantio-
selective polyanion binding (Fig. 12).66 C22-L-Lys and C22-D-Lys
are identical in every way apart from the chirality of the cationic
lysine ligands that end up displayed on the surface of the
SAMul nanostructure. Obviously, these two enantiomeric ligands
have identical critical micelle concentrations, and form systems
with identical dimensions and surface charges – just different
chiralities. Interestingly, however, they bound to heparin and
DNA with significant differences. Heparin bound preferentially
to C22-D-Lys, while DNA had a preference for C22-L-Lys. This
clearly demonstrates that charge density is not the only factor
controlling binding affinity, and that the precise molecular-
scale optimisation of the nanoscale binding interface plays a
key role. Although chiral recognition of these polyanions is not
new,67 it was surprising that our simple SAMul nanostructures
could achieve this. Furthermore, this was the first report in which
different polyanions expressed opposite enantioselectivities. Given
the crucial roles played by each of these highly charged anions, we
speculate whether such selectivities may help biology regulate the
ubiquitous and complex ‘polyanion world’.
Extending this research further, chiral amino acid modi-
fications were made to a very simple amphiphile (C16-Lys and
C16-Gly-Lys).
68 The presence of a glycine spacer unit between
Fig. 11 (top) TGD-G2 and (bottom) PAMAM-G2 dendrimers bound to
heparin at a charge excess of 0.4 using MD modelling methods. TGD and
PAMAM molecules are portrayed as pink and green sticks-and-balls,
respectively. Heparin is shown as a chain of L-iduronic acid (blue) and
D-glucosamine (light blue) alternating units. Some Na+ and Cl counterions
are shown as small and large pink and grey shaded spheres respectively.
Water is not shown for clarity. It is evident that PAMAM is better able to
adapt its structure and bind along the polyanionic heparin chain, unlike
shape-persistent TGD.
Fig. 12 Compounds C22-L-Lys and C22-D-Lys and the charge excess of
each required to achieve 50% displacement of MalB from heparin and
EthBr from DNA at pH 7.4 (Tris–HCl, 10 mM, NaCl, 150 mM). Evidently,
heparin binds more strongly to C22-D-Lys and DNA binds more strongly
to C22-L-Lys.
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the hydrophobic unit and the cationic head-group was essential
in enabling chiral recognition. Modelling proposed that the
glycine spacer changed the polarity and shape of the amphiphile
and hence modified the self-assembled morphology, enabling
optimisation of the binding interface and yielding greater
selectivity.
We also explored the impact of ligand modification on
polyanion binding in SAMul systems.69 Palmitic acid was
modified with a series of amines with diﬀerent charges, yield-
ing three diﬀerent micellar assemblies (C16-SPM [4+], C16-SPD
[3+] and C16-DAPMA [2+]) (Fig. 13). Overall, C16-SPM formed the
loosest assembly, while C16-DAPMA was the most eﬀectively
packed with the highest surface charge. Intriguingly in our
DNA-binding assays, DNA bound C16-SPM 4 C16-DAPMA 4
C16-SPD, whereas heparin bound C16-SPD 4 C16-SPM 4
C16-DAPMA. Clearly therefore, neither simple ligand charge
nor micellar surface charge density, control the binding event.
A combination of experimental (isothermal calorimetry, ITC)
and simulation (multiscale modelling) techniques provided
insight into the thermodynamics of binding. We proposed
inherent diﬀerences between the polyanions, suggesting that
DNA was shape-persistent while heparin was adaptive (Fig. 13).
As such, shape-persistent DNA simply binds the charges it is
presented with as best as it can. Spermine ligands are well
adapted to bind DNA, have the highest individual charge, and
therefore C16-SPM was the preferred binding partner. Conver-
sely, adaptive heparin can modify its shape on binding to the
SAMul nanostructure, meaning both ligand and polyanion
optimise their mutual interactions. This led to C16-SPD being
preferred, with heparin adapting and optimising each individual
electrostatic interaction. This work indicates how selectivity may
be achieved in the polyanion world, and suggests fundamental
diﬀerences between polyanions. Interestingly, flexibility has
been highlighted as a key beneficial factor in biological heparin
binding proteins,70 which would agree with this view of heparin
as an adaptive binding partner and suggest it might have
genuine biological significance.
The hydrophobic unit can also aﬀect the SAMul binding
event. To demonstrate this, we synthesised a family of molecules
with the same cationic ligand (DAPMA) and a hydrophobic
aliphatic group with eighteen carbon atoms, but having one,
two, or three alkenes within the hydrophobic chain (C18-1, C18-2
and C18-3, Fig. 14).
71 The presence of more alkenes led to
geometric distortion, yielding larger self-assembled multivalent
(SAMul) nanostructures and hence modifying the ligand dis-
play. Polyanion binding was studied using dye displacement
assays and ITC, with data in agreement that heparin bound
most eﬀectively to C18-1, and DNA to C18-3, even though the
molecular-scale structural diﬀerences of the SAMul systems are
buried in the hydrophobic core. Multiscale modelling suggested
that adaptive heparin somewhat folds around smaller C18-1
assemblies maximising enthalpically favourable interactions,
while ‘shape-persistent’ DNA cannot easily bend, and forms a
similar number of interactions with each assembly, but with less
entropic cost for binding to the larger flatter surface of C18-3.
Once again, this provides fundamental insight into electrostatic
molecular recognition in biologically relevant systems and
suggests not all polyanions are the same.
The impact of buﬀer on SAMul electrostatic recognition has
also been studied.72 ITC and dye displacement assays indicated
that the binding of C16-DAPMA to heparin was significantly
stronger in Tris–HCl 4 HEPES 4 phosphate. This results
from interactions between the anionic buffer component
Fig. 13 (top) Structures of compounds investigated as part of the ligand
modification study, and (bottom) equilibrated atomistic molecular dynamics
(MD) simulation snapshots of SAMul micelles binding DNA (upper panel,
orange) and heparin (lower panel, firebrick), from left to right: C16-DAPMA
(light grey (C16) and plum (DAPMA)), C16-SPD (lime green (C16) and forest
green (SPD)), and C16-SPM (steel blue (C16) and navy blue (SPM)). Hydrogen
atoms, water molecules, ions and counterions are not shown for clarity. The
shape persistence of DNA which favours C16-SPM and more adaptive nature
of heparin favouring C16-SPD are evident in this modelling study.
Fig. 14 Structures of SAMul systems used to study the impact of the
hydrophobic unit on ligand display and multivalent binding. C18-1 (grey)
forms a more tightly packed assembly which adaptive heparin (orange) is
better able to wrap around, while the larger assemblies formed by C18-3
(blue/grey) are more compatible with maximising interactions with shape
persistent DNA (red) that cannot bend around the SAMul nanostructure.
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(phosphate/sulfonate/chloride) and the cationic binder. Such
interactions occur in 10 mM buffer, even in the presence of
150 mM NaCl. Furthermore, even a ‘Good’ buffer such as
HEPES competes at the binding interface. The impact of buffer
on SAMul nanostructures was even more significant than on a
simple heparin binder such asMalB. ITC was used to determine the
difference in DG for heparin binding between Tris–HCl and phos-
phate buffer. This buffer induced difference was 1.20 kcal mol1
for MalB (14.1% of the total) but rose to 1.77 kcal mol1 for
C16-DAPMA (21.9% of the total). The greater adverse effect of
competitive buffers on SAMul systems arose from a decrease in
the larger enthalpic term resulting from the highly charged
multivalent binding interface. This study highlighted the
importance of choosing even often-overlooked species, such as
buffers,73 very carefully in molecular recognition studies and
demonstrated that highly charged nanoscale binding interfaces
are sensitive to buffer.
Once again, by starting with an application in mind, we have
uncovered new fundamental concepts. This has led to the
emergence of ideas such as shape-persistent and adaptive
multivalency. Furthermore, the medical drive behind our work
has meant all of our anion binding studies have transitioned
from organic solvents into, as a minimum, buﬀered water with
high levels of competitive salt. We believe that understanding
binding interactions in highly competitive and complex
media (e.g. buﬀers, human serum or blood), with multiple
competing influences – will emerge as a key theme of supra-
molecular chemistry over the coming 10 years, with many more
chemists starting to explore this fascinating but challenging
‘real world’.
From organogels to hydrogels –
pursuing applications in drug delivery
Another thing that became apparent watching major transplant
surgery, was the need for large amounts of pharmaceutical
intervention, such as painkillers, anti-rejection drugs and a
wide range of supplements. After surgery, such drugs are mostly
delivered intravenously, and then later orally. Reflecting on the
extensive drug treatment made me reflect on diﬀerent modes of
drug delivery, which may be more eﬀective for long-term
treatment or controlled drug release. In particular, my research
team had been developing extensive expertise in working with
self-assembled gel-phase materials74 which form as a result of
non-covalent interactions assembling molecular-scale building
blocks in a ‘1-dimensional’ manner into extended nanofibres,
that ultimately form a sample spanning network which manifests
itself macroscopically as a gel (Fig. 15).75
Our fundamental research on ‘supramolecular gels’ had,
for example, demonstrated that such materials were highly
responsive – capable of selecting and releasing specific compo-
nents from complex mixtures76 and evolving their structures
over time in response to different stimuli.77 We realised that
these would be useful features in materials for drug delivery.
There was just one problem – all of our long-established gels
were only stable in organic solvents such as toluene, being held
together by intermolecular hydrogen bond interactions between
peptide building blocks. The presence of competitive media was
simply too disruptive, leading to fibril disassembly and gel
breakdown. We therefore set ourselves the challenge of develop-
ing a simple new commercially-viable hydrogelator that operated
in water. Such a system could open up a range of biomedical
(and other) applications.78
For inspiration, we turned to one of the best known families
of gelator – 1,3:2,4-dibenzylidenesorbitol (DBS) – about which
we wrote a key review.79 First reported by Meunier in 1891 as a
product of the reaction between sorbitol and two equivalents of
benzaldehyde,80 DBS gels have been widely applied in an indus-
trial setting over the past century. DBS has been self-assembled in
polymers to enhance transparency.81 It has also been used as the
gelation component in personal care products such as deodorant
sticks.82 However, DBS is always used in organic solvents or
polymer melts. In pure water, it struggles to self-assemble into
an effective gel owing to its poor solubility – indeed, solvent
effects on DBS self-assembly have recently been studied in
detail.83 DBS is often described as a butterfly-like surfactant, with
the sorbitol unit as the body and the aromatic rings as the wings.
It assembles into fibrils as a result of intermolecular hydrogen
bond interactions via the body and solvophobic/p–p interactions
between the wings (Fig. 16), with the balance depending on the
solvent in which the gelator assembles.
We therefore decided to target hydrogels using this simple,
yet versatile, molecular framework. Derivatives of DBS were
reasonably well-known, as benzaldehyde can simply be replaced
with a substituted benzaldehyde during synthesis. However, only
simple substituents (e.g.Me, F, etc.) had been used to modify the
performance for a specific industrial application.84 We wanted
to insert functional groups that might increase the solubility of
DBS in water, hence opening the possibility of hydrogel forma-
tion. Surprisingly, this had not previously been reported. Using a
methyl ester of 4-carboxybenzaldehyde gave access to DBS-COOMe,
and inserted a functional handle onto DBS that could be simply
converted into an acid (DBS-COOH)85 or an acylhydrazide
(DBS-CONHNH2)
86 (Fig. 16). Pleasingly, this strategy worked
and both of these compounds could be synthesised on large
Fig. 15 Schematic diagram of the self-assembly of gels from molecular-
scale building blocks assembling into fibrils, which aggregate into fibres and
ultimately for a sample-spanning network with macroscopic gel-phase
behaviour.
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scale and could form hydrogels – a very significant step forwards
for DBS chemistry. We further extended this family of hydrogels
by modifying DBS-COOH to yield DBS-Gly-COOH.87 Following
our discovery of these hydrogels, Knani and Alperstein’s com-
puter simulation suggested that hydrogen bonding between the
sorbitol ‘bodies’ of the gelator were weakened by the presence of
water, and that the aromatic rings were rigidified.88
The carboxylic acid, DBS-COOH, formed gels via protonation
of the highly soluble carboxylate anion, yielding the less soluble
carboxylic acid form, and allowing the ‘solid-like’ gel fibres to
assemble with a degree of controlled kinetics in order to form a
sample-spanning network.85 This was achieved using the well-
established glucono-d-lactone hydrolysis slow acidification
method, as pioneered by the Adams group.89 The acylhydrazide,
DBS-CONHNH2, was stable across the entire pH range from
2–12,86 and the solubility of this gelator was such that sample-
spanning gels could be formed simply by heating and cooling a
sample in water. Many well-established hydrogels are based on
carboxylic acids, and require pHmanipulation to form gels – we
noted that acylhydrazides may potentially be effective carboxylic
acid replacements in a wide-range of hydrogels.86 In this way,
a new insight into gelators emerged from our application-driven
hunt for new hydrogels.
We were then interested in the ability of these DBS-CONHNH2
gels to bind and release active agents with the ultimate goal of
controlled drug release. The ability of this gel to extract pollutant
dyes frommodel waste water was initially tested, as this is a quick
and easy visual test – it was rapidly possible to screen the gel
against a variety of different dyes in order to explore uptake
selectivity.86 Dye extraction was controlled both by the structure
of the dye, and pH. Fully-ionised dyes were less readily adsorbed
onto the self-assembled gel fibres, presumably as a consequence
of their higher water solubility. Changing pH altered the ionisa-
tion state of the dyes and hence provided a mechanism for
desorbing dyes from the gel, meaning the gel could be used for
repeat cycles of uptake and release. It is worth noting that this
strategy is of great interest for remediating polluted water –
indeed gels are highly effective in this application as a result of
the nanoscale fibres having high relative surface areas, able to
achieve very efficient uptake.90
Moving on from dyes towards biologically-relevant sub-
stances, we explored the ability of the DBS-CONHNH2 hydrogel
to bind active pharmaceutical ingredients (APIs) – specifically,
acid-functionalised non-steroidal anti-inflammatory drugs (NSAIDs),
such as ibuprofen and naproxen.91 The gel could form in the
presence of these APIs, and there were direct interactions
between the acid on the API and the NH2 group displayed on
the surface of the gel fibres – another form of self-assembled
multivalent (SAMul) ligand display (Fig. 17). Interestingly, the
APIs were immobilised at low pH values (o5), but once
the pH was increased, they were desorbed from the gel, as the
carboxylic acid became ionised and no longer interacted with the
gel nanofibres. These hydrogels therefore achieved pH-triggered
drug release of pharmaceutical relevance – the stomach has low
pH (2–3) conditions, while the intestine, where drug release is
most desirable is pH 7–8. As such, gels based on DBS-CONHNH2
can achieve targeted delivery of acid-functionalised APIs. Inter-
estingly, naproxen causes well-documented side effects within
the stomach, which can be particularly severe for patients who
have longer-term use of such drugs, for example after major
surgery.92Most importantly, however, this study exemplified that
self-assembled multivalent gel-phase materials can achieve con-
trolled binding and release of a biologically active species in the
presence of a triggering stimulus. We suggest that in the future,
this might be of relevance to controlled delivery of a wide range
of acid-functionalised APIs, such as statins.
One disadvantage of self-assembled supramolecular hydro-
gels, such as DBS-CONHNH2, is that they are mechanically
weak materials. This may be desirable for drug formulation for
(e.g.) transdermal delivery, but is less suitable for delivery via an
Fig. 16 (top) New DBS hydrogelators DBS-COHNH2, DBS-COOH and
DBS-Gly-COOH developed by us, and (bottom) self-assembly mode of
DBS-CONHNH2 as modelled by Knani and Alperstein.
88
Fig. 17 Image of hydrogel formed by DBS-CONHNH2 and naproxen.
Structures of the gelator and some acid-functionalised non-steroidal anti-
inflammatory drugs. Schematic of pHmediated drug uptake and release as a
result of interactions with the self-assembled nanofibre surfaces.
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oral route. This weakness is a direct result of the reversible non-
covalent forces that hold together self-assembled gels. In con-
trast, polymer gels can be significantly more robust owing to
the covalent constitution of the network. As such, we reasoned
that combining the two types of material into hybrid hydrogels
would oﬀer significant synergistic advantages (Fig. 18). To demon-
strate this principle, we combined self-assembling low-molecular-
weight gelator (LMWG) DBS-COOH with a typical polymer gelator
(PG), agarose.85 The LMWG assembles on lowering pH, while the
PG network forms by applying a heat–cool cycle. Using orthogonal
methods of network formation is a useful tool for enabling their
sequential formation. We demonstrated that the LMWG network
could then be disassembled by raising pH, while the agarose
PG network ensured the overall hybrid hydrogel remained
intact. As such, these materials had both responsive and robust
components. We reviewed this general approach to hybrid
LMWG/PG gels, collecting together all the examples-to-date in
a field-defining article.93
Extending this approach, we recently combinedDBS-CONHNH2
with a photo-initiated crosslinked polymer hydrogel based on
poly(ethyleneglycol dimethacrylate) (PEGDM) and loaded the
resulting gels with naproxen.94 The PEGDM provides mecha-
nical strength and gives the hybrid hydrogel a self-supporting
nature, while the self-assembled DBS-CONHNH2 network inter-
acts with naproxen and controls its release depending on the
pH of the surroundings. On exposing diﬀerent sides of the gel
to solutions with diﬀerent pH values, directional release of the
drug was achieved, controlled by the pH. We refer to this as
directional release (Fig. 19). It opens the longer-term possibility
of making gels with defined shapes in which the self-assembled
network controls drug release in a directional manner under
the influence of diﬀerent stimuli towards a desired target. Such
gels could, for example, be loaded with therapeutic agents and
implanted into patients after surgery, releasing the drugs in a
directional manner in response to biological stimuli. Further
research in this direction is currently in progress in our labs.
Smart multi-functional hydrogels as
tissue engineering scaffolds to address
transplantation problems
It is tempting to think that transplantation, as successfully
achieved for Sam, is a solution to problems faced by patients with
cystic fibrosis, but sadly this is not the case. Many CF patients die
waiting for a transplant,95 and even for those patients lucky
enough to receive a transplant, median life expectancy post-
transplant remains stubbornly just 5–10 years – primarily a result
of problems with chronic rejection.96 The only option for patients
with this problem is a second transplant – but ethical and
surgical considerations mean this is a rare event.97 Across all
types of transplantation, the limiting factor is the lack of suitable
donor organs. As such, regenerative medicine, and more specifi-
cally tissue engineering has emerged as a strategy for potentially
growing organs and other tissue ex vivo and then implanting
them into a patient.98 Given the ongoing revolution in stem cell
technology, it is possible, at least in principle, to harvest stem
cells from a patient, and then grow a replacement organ from
these cells containing their own genetic material. Not only would
this solve problems with organ supply, but it would eliminate the
major problems associated with organ rejection and has the
potential to transform lung transplant survival statistics.99 In
order to grow an organ, a matrix/scaffold is required, and gels
have emerged as one fascinating class of material that might be
used.100 As soft wet materials, gels can be compatible with
growing tissue and help direct cell growth – indeed the extra-
cellular matrix is itself a type of gel.101 Given the potential
transformative effects of such medicinal technology, the strong
personal motivation given my husband’s lung allograft rejec-
tion, and our existing expertise in self-assembled gels, we were
impatient to get involved in this area of research.
It is worth emphasising that much tissue engineering
research has been carried out using polymer hydrogels.100
However, we (and others) reasoned that self-assembled low-
molecular-weight gels may oﬀer significant advantages for
tissue engineering. Self-assembled materials have the advan-
tage of being highly responsive, and they can disassemble into
individual molecular-scale building blocks. This oﬀers a signi-
ficant advantage for 3D tissue engineering, in which tissue is
grown within a gel, as the gel could be simply removed, and the
tissue recovered.102 Some early work in this field achieved eye-
catching in vivo results using self-assembled hydrogels based
on relatively complex peptides, including nerve regeneration
within the optic nerve and spinal cord, restoring function in
disabled animal models.103 However, there has been less research
making use of very simple low-molecular-weight gelators for tissue
engineering.
In many ways, it is relatively straightforward to perform
simple cell tissue culture on gels. What is more challenging,
Fig. 18 Schematic of hybrid hydrogels formed by combination of a
responsive self-assembling LMWG network and a more robust polymer
gel (PG) network.
Fig. 19 Directional release of naproxen from a hybrid hydrogel based on
DBS-CONHNH2 and PEGDM with release of the drug occurring prefer-
entially into a solution of pH 7 in comparison to one of pH 3.
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is to encourage the cells to do interesting and sophisticated
things, which may be required for the growth of complex tissue
such as organs. As such, our initial focus has been on adding
functionality to our hydrogels so that not only can we grow
tissue, but hopefully we can do it in smarter and more directed
ways. In this way, heading towards our ultimate application, we
reasoned that new fundamental insights would also emerge. In
particular, we targeted incorporating the following features into
LMWG hydrogels:
 Binding and release of active agents (this could help direct,
control, or respond to, cell growth). Our work described in the
previous section on controlled drug release is a step towards
this goal.
 Conductive gels (tissue grown on such materials may then
be stimulated electrically to achieve diﬀerential growth).104
 Spatially resolved multicomponent materials with multiple
domains, each having diﬀerent properties (this may facilitate
spatially resolved and defined tissue growth).
These innovations would yield smarter LMWG hydrogels
moving the state-of-the-art significantly forwards. In the long
run, this may generate soft materials with the capacity to exert
both temporal and spatial control over cell growth, directing
biological outcomes, with the gels being capable of precise
levels of intervention, and responsive to the growing tissue.
Controlled release
As described above, we have demonstrated thatDBS-CONHNH2 can
achieve controlled encapsulation and release of acid-functionalised
drugs. We extended this work to develop gels capable of the
encapsulation and release of heparin (Fig. 20).105 Heparin
encourages the angiogenesis of growing tissue and also recruits
other growth factors. As such, it can exert a significant influence
on growing tissue.106 We combined LMWG DBS-COOH with PG
agarose (to provide robustness) in a hybrid hydrogel formulation,
along with heparin. The LMWG endows the hybrid hydrogel with
pH-responsive behaviour, while the PG provides mechanical
robustness. The rate of heparin release could be controlled
through network density and composition, with the LMWG and
PG behaving diﬀerently as a result of interactions between the
LMWG and heparin. The addition of a micellar SAMul heparin
binder (C16-DAPMA, described above) to the formulation comple-
tely inhibited heparin release through binding. Overall, this
research demonstrated that a multi-component approach can
yield exquisite control over self-assembled materials with all four
components playing individual roles within the hybrid material.
We reason that controlling orthogonality in such systems will
underpin further development of controlled release systems for
tissue engineering applications.
Conductive gels
With the target of conductive gels, we demonstrated that DBS-
CONHNH2 selectively extracts precious metals from electronic
waste.107 The acylhydrazides reduced these metals in close
proximity to the gel nanofibres, and as a result, immobilised
metal nanoparticles were generated, the vast majority of which
were organised along the nanofibrillar network (Fig. 21). In the
case of gold or silver, these gels had useful conductivities (Fig. 21).
After partial drying to contract the network, the AuNP-loaded
gel had a higher conductance than the equivalent hydrogel
loaded with single walled carbon nanotubes. This gel was used
to modify an electrode surface, which was functional for
electrocatalysis. Given that hydrogels are often compatible with
biological tissue, conductive gels oﬀer a unique mechanism by
Fig. 20 Hybrid hydrogel based on DBS-COOH (LMWG), agarose (PG),
heparin and C16-DAPMA heparin-binding micelles. All four components
could operate independently of one another. The SEM image of the hybrid
hydrogel formed by DBS-COOH and agarose showed both larger fibres
associated with DBS-COOH (black arrows) and smaller nanofibres asso-
ciated with agarose (white arrows). The TEM image of the hybrid hydrogel
in the presence of heparin and heparin-binding micelles showed both gel
nanofibres and hierarchically-organised C16-DAPMA micelles bound to
heparin.
Fig. 21 Use of DBS-CONHNH2 hydrogels to extract precious metals
(e.g. Au) from mixtures with reduction to metal nanoparticles. TEM image
demonstrates the organisation of metal nanoparticles on the nanofibre
network. Graph demonstrates conductance of the DBS-CONHNH2 hydro-
gel formulated as a hybrid gel with agarose to give physical robustness,
and hybrid hydrogels modified with AgNPs, AuNPs or SWNTs. On drying by
30% to bring AuNPs into close proximity, the AuNP-modified gels showed
excellent conductances.
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which cells could be stimulated electrically.104 Work towards
this challenging target is in progress.
Spatially resolved gels
Spatial resolution has considerable potential for tissue engin-
eering, yet has been very rarely achieved with supramolecular
gels,108 most of which are simply presented as gels formed in
up-turned sample vials. In order to achieve spatial resolution
within our gels, we turned for inspiration to the burgeoning field
of polymer hydrogels – many of which are applied for tissue
engineering.109 Although photo-activation is quite widely used in
such materials as a way of achieving spatial control, perhaps
surprisingly, it has been less wisely applied to self-assembled
supramolecular gels to achieve spatial control. We initially
developed a system in which we patterned a rigid crosslinked
photo-initiated polymer hydrogel based on PEGDM within a soft
DBS-COOH network using photo-patterning methods under a
laser-jet-printed acetate mask, fabricating a multi-domain gel
with hard regions (containing both PEGDM and DBS-COOH)
and soft regions (containing only DBS-COOH) (Fig. 22).110 Dye
diffusion was rapid through the soft supramolecular gel domain,
but prevented by the rigid PEGDM network. This indicates that
spatially resolved control over the diffusion and release of active
ingredients should be possible. Indeed, the naproxen-loaded gel
system described above (Fig. 19) was used to further demonstrate
this principle.94
LMWG hydrogelator, DBS-Gly-COOH, opened up the possi-
bility of patterning one self-assembled gel within another for
the first time.87 The diﬀerent pKa values of DBS-COOH (ca. 5.5)
and DBS-Gly-COOH (ca. 4.5) mean they assemble sequentially
as the pH is lowered. Careful control of conditions allowed us
to form the DBS-COOH network using an equimolar chemical
source of acid (glucono-d-lactone), with the DBS-Gly-COOH net-
work being subsequently assembled by activating a photo-acid
(diphenyliodonium nitrate) under UV-stimulation. Performing the
photo-acidification through amask allowed us to ‘write’ aDBS-Gly-
COOH network into a preformed DBS-COOH gel (Fig. 23). Inter-
estingly, the first gel network is essential if the second network is
to be patterned in with good spatial resolution. We reason that
pattered multi-domain self-assembled LMWG gels such as these
may spatially direct cell growth and then at a later stage, unlike
many polymer gels, can be easily disassembled.
We suggest that combining controlled release, conductivity
and spatial control within LMWGs yields a unique platform of
technologies to develop innovative tissue engineering materials.
To demonstrate these systems are compatible with tissue growth,
experiments were performed with 3T3 Mouse Fibroblast cells,
and it was shown that these could indeed grow eﬀectively on
simple DBS-CONHNH2.
111 A major EPSRC grant is now enabling
us to translate our fundamental gel technologies into controlled
tissue engineering materials. Indeed, we look forward to conti-
nuing to develop new fundamental approaches and strategies
in gel-phase materials and translating these into medicinal
applications. We believe that explorations of smart self-assembled
materials in biomedical applications will occupy much of our
attention for the next 10 years and beyond.
Conclusions
In summary, this paper reflects on developments in my
research group at York over the past 10 years in York. Inspired
by the health problems of my husband, we have shifted some of
Fig. 22 Spatially resolved hybrid hydrogel in which ‘Y-shaped’ PEGDM has
been patterned into DBS-COOH. As can be seen, the DBS-COOH domain
is very soft, while the PEGDM/DBS-COOH hybrid hydrogel is robust and
can be lifted out of the gel.
Fig. 23 Graph reporting the results of NMR experiments demonstrating
that DBS-COOH assembles in the presence of glucono-d-lactone before
DBS-Gly-COOH as a result of its higher pKa value. The DBS-Gly-COOH
network then assembles second – which can be achieved by activation of
the photoacid. Performing this latter process under a mask yields a material
in which DBS-Gly-COOH is patterned into DBS-COOH with excellent
spatial resolution.
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our research into a more applied direction. All of our self-
assembling systems are now being studied in aqueous, highly
complex, media – a significant challenge for supramolecular
chemistry. Furthermore, in the process of targeting new
applications, we have developed enhanced theoretical under-
standing and initiated a number of new concepts in self-
assembly science.
 Flexible multivalency: screening and sacrifice. Flexibility in
multivalent binding systems has advantages – e.g., flexible
ligands can reorganise and shield electrostatic binding inter-
faces from competitive electrolyte.16
 Self-assembled multivalency (SAMul). Self-assembly can
organise dynamic tunable multivalent ligand arrays.26,27,29a,54
 Temporary ‘on–off’ multivalency. Multivalent arrays that can
degrade and/or disassemble enable high-aﬃnity multivalency to
be turned oﬀ, limiting persistence and potential toxicity.20,38,40
 Adaptive and shape persistent multivalency. Fundamental
diﬀerences between the binding of polyanionic heparin and DNA
suggest the former is adaptive and the latter shape-persistent.60,69,71
 Selective electrostatic binding. Electrostatic binding does
not only depend on charge density – selectivity can be achieved
based on the precise details of ligand structure.66,68,69
 Specific buﬀer eﬀects. The choice of buﬀer, an often over-
looked component, can impact on electrostatic binding, changing
dissociation constants up-to 20-fold.72
 New DBS hydrogels. In the search for biorelevant systems,
three new commercially-relevant hydrogelators based on 1,3:2,4-
dibenzylidenesorbitol (DBS) have been developed.85–87
 Supramolecular controlled release. Gel nanofibres that form
supramolecular interactions with (e.g.) drug molecules can
control release profiles.91,94
 LMWG/PG hybrid hydrogels. Hybrid gels combining LMWG
and PG gels can gain the advantage of synergistic eﬀects from
both networks.85,93,110
 Spatially resolved self-assembled hydrogels. Spatial resolution
can fabricate complex self-assembled gels – moving LMWGs
beyond being simple gels in vials.87,94,110
In addition to these fundamental insights and new strategic
approaches, our research now approaches varied applications,
and progress is ongoing in each of the following biomedically-
relevant areas:
(i) Gene delivery. SAMul systems have been optimised in
terms of morphology, and synergistic advantages of mixing
diﬀerent self-assembling units have been demonstrated.
Optimised systems can achieve eﬀective siRNA delivery in vitro
and do not elicit an inflammatory response in vivo.
(ii) Coagulation control. Clotting times can be controlled in
coagulation assays in human plasma using SAMul systems.
Further stabilisation of self-assembled systems in highly com-
petitive biological conditions is of key ongoing importance
before translation in vivo.
(iii) Heparin sensing. Mallard Blue operates eﬀectively in
human serum/plasma and detects heparin using simple readouts.
Further work to develop dual wavelength sensors is ongoing.
(iv) Drug formulation. Key drugs (e.g. naproxen) can be
formulated in gels for controlled release. Gels are currently
being tested in a range of settings, and for diﬀerent modes of
drug delivery, with directional release at controlled rates from
shaped gels opening new paradigms in drug delivery.
(v) Tissue engineering. Combining release of active ingredi-
ents, conductivity and spatial resolution should encourage
stem cells to grow in complex and sophisticated ways as a
result of the chemistry programmed into self-assembled gels.
As illustrated by this article, the last ten years in our
laboratory have been fruitful and stimulating. Approaching
applied targets has not only provided a guiding principle
behind some of our research, it has motivated young researchers,
and inspired us to persevere through the inevitable string of
paper and grant rejections. Furthermore, as well as heading
towards these vital medical applications, we feel we have
also become better fundamental scientists – developing new
paradigms that are increasingly being applied in other
scientists’ labs.
As scientists, we rarely talk about the personal – after all, the
underpinning philosophy of science is that whoever performs
the studies, the results will be the same. However, I strongly
believe that personal experiences and interests can direct project
development and enable intellectual connections between
diverse areas of science in unique ways. The personal really does
matter, and we need to support diverse scientists, so that diverse
solutions to problems can be found.112 As I write this, given
Sam’s health problems, it is difficult to know what the future will
bring personally, but I know that professionally, the decision to
let the ‘personal’ influencemy direction of academic travel is one
that I will never regret.
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